Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gynecology

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 94 articles: HTML format

Single Articles

April 2024
1. MUTLU SUTCUOGLU B, Sutcuoglu O
   Interpretation of the EORTC-55954 Trial: Does the Response to Neoadjuvant Chemotherapy Have an Effect on Disease Outcome?
   J Clin Oncol. 2024;42:1204-1205.
   PubMed    
   
   
   
2. HAN CY, Lu KH, Corrigan G, Perez A, et al
   Normal Risk Ovarian Screening Study: 21-Year Update.
   J Clin Oncol. 2024;42:1102-1109.
   PubMed     Abstract available
   
   
   March 2024
3. CHARGARI C, Wasserman J, Gabro A, Canlobre G, et al
   Vulvar Carcinoma: Standard of Care and Perspectives.
   J Clin Oncol. 2024;42:961-972.
   PubMed     Abstract available
   
   
   
4. LUO PH, Mo DC, Wang HL, Liang XJ, et al
   Predicted Value of PD-L1 for Patients With Cervical Cancer Treated With Pembrolizumab.
   J Clin Oncol. 2024 Mar 7:JCO2302479. doi: 10.1200/JCO.23.02479.
   PubMed    
   
   
   February 2024
5. LORUSSO D, Raspagliesi F, Ronzulli D, Valabrega G, et al
   Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
   J Clin Oncol. 2024 Feb 5:JCO2301225. doi: 10.1200/JCO.23.01225.
   PubMed     Abstract available
   
   
   
6. PAVLIK EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR, et al
   Compelling Story of Ovarian Cancer Screening.
   J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424.
   PubMed    
   
   
   January 2024
7. WESTIN SN, Moore K, Chon HS, Lee JY, et al
   Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
   J Clin Oncol. 2024;42:283-299.
   PubMed     Abstract available
   
   
   
8. TJOKROWIDJAJA A, Friedlander ML, Ledermann JA, Coleman RL, et al
   Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
   J Clin Oncol. 2024 Jan 12:JCO2301182. doi: 10.1200/JCO.23.01182.
   PubMed     Abstract available
   
   
   
9. PIJNENBORG JMA, van Weelden WJ, Reijnen C, Xanthoulea S, et al
   Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification.
   J Clin Oncol. 2024;42:8-12.
   PubMed    
   
   
   December 2023
10. VERGOTE I, Perez-Fidalgo JA, Hamilton EP, Valabrega G, et al
    Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
    J Clin Oncol. 2023;41:5400-5410.
    PubMed     Abstract available
    
    
    November 2023
11. HAN K, Zou J, Zhao Z, Baskurt Z, et al
    Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.
    J Clin Oncol. 2023 Nov 16:JCO2300954. doi: 10.1200/JCO.23.00954.
    PubMed     Abstract available
    
    
    
12. LAVERY JA, Boutros PC, Scott JM, Tammela T, et al
    Pan-Cancer Analysis of Postdiagnosis Exercise and Mortality.
    J Clin Oncol. 2023;41:4982-4992.
    PubMed     Abstract available
    
    
    
13. MONK BJ, Colombo N, Tewari KS, Dubot C, et al
    First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
    J Clin Oncol. 2023 Nov 1:JCO2300914. doi: 10.1200/JCO.23.00914.
    PubMed     Abstract available
    
    
    
14. ST LAURENT J, Liu JF
    Treatment Approaches for Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2023 Nov 1:JCO2301771. doi: 10.1200/JCO.23.01771.
    PubMed     Abstract available
    
    
    October 2023
15. AREND RC, Monk BJ, Shapira-Frommer R, Haggerty AF, et al
    Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
    J Clin Oncol. 2023 Oct 31:JCO2202915. doi: 10.1200/JCO.22.02915.
    PubMed     Abstract available
    
    
    
16. FLEMING GF
    Flashback Foreword: Concurrent Chemotherapy/Radiotherapy for Cervical Cancer.
    J Clin Oncol. 2023;41:4603-4604.
    PubMed    
    
    
    September 2023
17. HOREWEG N, Nout RA, Jurgenliemk-Schulz IM, Lutgens LCHW, et al
    Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
    J Clin Oncol. 2023;41:4369-4380.
    PubMed     Abstract available
    
    
    
18. SPRIGGS DR, Fleming GF
    Flashback Foreword: Cytoreductive Surgery for Ovarian Carcinoma and Carboplatin + Paclitaxel in Ovarian Cancer.
    J Clin Oncol. 2023;41:4063-4064.
    PubMed    
    
    
    
19. INGHAM M, Allred JB, Chen L, Das B, et al
    Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
    J Clin Oncol. 2023;41:4154-4163.
    PubMed     Abstract available
    
    
    
20. KENTER GG, Greggi S, Vergote I, Katsaros D, et al
    Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994.
    J Clin Oncol. 2023 Sep 1:JCO2202852. doi: 10.1200/JCO.22.02852.
    PubMed     Abstract available
    
    
    August 2023
21. VERGOTE I, Van Nieuwenhuysen E, O'Cearbhaill RE, Westermann A, et al
    Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
    J Clin Oncol. 2023 Aug 31:JCO2300720. doi: 10.1200/JCO.23.00720.
    PubMed     Abstract available
    
    
    
22. KURTZ JE, Pujade-Lauraine E, Oaknin A, Belin L, et al
    Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
    J Clin Oncol. 2023 Aug 29:JCO2300529. doi: 10.1200/JCO.23.00529.
    PubMed     Abstract available
    
    
    June 2023
23. COLOMBO N, Van Gorp T, Matulonis UA, Oaknin A, et al
    Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
    J Clin Oncol. 2023 Jun 26:JCO2202624. doi: 10.1200/JCO.22.02624.
    PubMed     Abstract available
    
    
    
24. ZHANG X, Elsaid MI, DeGraffinreid C, Champion VL, et al
    Impact of the COVID-19 Pandemic on Cancer Screening Delays.
    J Clin Oncol. 2023;41:3194-3202.
    PubMed     Abstract available
    
    
    
25. MAKKER V, Colombo N, Herraez AC, Monk BJ, et al
    Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
    J Clin Oncol. 2023;41:2904-2910.
    PubMed     Abstract available
    
    
    May 2023
26. NISHIKAWA T, Hasegawa K, Matsumoto K, Mori M, et al
    Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
    J Clin Oncol. 2023;41:2789-2799.
    PubMed     Abstract available
    
    
    
27. KINNEY AY, Walters ST, Lin Y, Lu SE, et al
    Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    J Clin Oncol. 2023;41:2767-2778.
    PubMed     Abstract available
    
    
    
28. STROOT IAS, Brouwer J, Bart J, Hollema H, et al
    High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors.
    J Clin Oncol. 2023;41:2523-2535.
    PubMed     Abstract available
    
    
    
29. BERNSTEIN E, Lev-Ari S, Shapira S, Leshno A, et al
    Data From a One-Stop-Shop Comprehensive Cancer Screening Center.
    J Clin Oncol. 2023;41:2503-2510.
    PubMed     Abstract available
    
    
    April 2023
30. REYNOLDS AC, McKenzie LJ
    Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options.
    J Clin Oncol. 2023;41:2281-2292.
    PubMed     Abstract available
    
    
    March 2023
31. FU S, Yao S, Yuan Y, Previs RA, et al
    Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
    J Clin Oncol. 2023;41:1725-1734.
    PubMed     Abstract available
    
    
    
32. VIDRINE JI, Sutton SK, Wetter DW, Shih YT, et al
    Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2023 Mar 15:JCO2201228. doi: 10.1200/JCO.22.01228.
    PubMed     Abstract available
    
    
    February 2023
33. MAKKER V, Aghajanian C, Cohn AL, Romeo M, et al
    A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.
    J Clin Oncol. 2023;41:974-979.
    PubMed     Abstract available
    
    
    
34. SUN R, Huang B, Wei LJ
    Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer.
    J Clin Oncol. 2023 Feb 10:JCO2202596. doi: 10.1200/JCO.22.02596.
    PubMed    
    
    
    January 2023
35. MATULONIS UA, Lorusso D, Oaknin A, Pignata S, et al
    Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
    J Clin Oncol. 2023 Jan 30:JCO2201900. doi: 10.1200/JCO.22.01900.
    PubMed     Abstract available
    
    
    
36. KONSTANTINOPOULOS PA, Lee EK, Xiong N, Krasner C, et al
    A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
    J Clin Oncol. 2023;41:599-608.
    PubMed     Abstract available
    
    
    
37. CASTLE PE, Wentzensen N
    Clarifying the Equivocal Diagnosis of Cervical Intraepithelial Neoplasia 2: Still a Work in Progress.
    J Clin Oncol. 2023;41:419-420.
    PubMed    
    
    
    
38. SCHMID MP, Lindegaard JC, Mahantshetty U, Tanderup K, et al
    Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study.
    J Clin Oncol. 2023 Jan 4:JCO2201096. doi: 10.1200/JCO.22.01096.
    PubMed     Abstract available
    
    
    
39. CRABB SJ, Hussain S, Soulis E, Hinsley S, et al
    A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:54-64.
    PubMed     Abstract available
    
    
    
40. YOU B, Sehgal V, Hosmane B, Huang X, et al
    CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
    J Clin Oncol. 2023;41:107-116.
    PubMed     Abstract available
    
    
    December 2022
41. KINDLER HL, Hammel P, Reni M, Van Cutsem E, et al
    Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    J Clin Oncol. 2022;40:3929-3939.
    PubMed     Abstract available
    
    
    
42. COHEN CM, Wentzensen N, Castle PE, Schiffman M, et al
    Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype.
    J Clin Oncol. 2022 Dec 1:JCO2201424. doi: 10.1200/JCO.22.01424.
    PubMed     Abstract available
    
    
    November 2022
43. BEAVIS AL, Fader AN
    Surveillance Strategies in Endometrial Cancer Care: Why Less Represents Progress.
    J Clin Oncol. 2022;40:3790-3795.
    PubMed    
    
    
    
44. HERZOG C, Marin F, Jones A, Evans I, et al
    A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets.
    J Clin Oncol. 2022;40:3828-3838.
    PubMed     Abstract available
    
    
    
45. ZOLA P, Ciccone G, Piovano E, Fuso L, et al
    Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial.
    J Clin Oncol. 2022;40:3817-3827.
    PubMed     Abstract available
    
    
    
46. ZHANG J, Liu M
    Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy.
    J Clin Oncol. 2022;40:3783.
    PubMed    
    
    
    
47. PFISTERER J, Joly F, Kristensen G, Rau J, et al
    Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
    J Clin Oncol. 2022 Nov 4:JCO2201010. doi: 10.1200/JCO.22.01010.
    PubMed     Abstract available
    
    
    October 2022
48. YOU B, Purdy C, Copeland LJ, Swisher EM, et al
    Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
    J Clin Oncol. 2022 Oct 17:JCO2201207. doi: 10.1200/JCO.22.01207.
    PubMed     Abstract available
    
    
    
49. MARCHETTI C, Fagotti A, Scambia G
    Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors.
    J Clin Oncol. 2022 Oct 6:JCO2201585. doi: 10.1200/JCO.22.01585.
    PubMed    
    
    
    
50. THIEL KW, Devor EJ, Filiaci VL, Mutch D, et al
    TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
    J Clin Oncol. 2022;40:3289-3300.
    PubMed     Abstract available
    
    
    September 2022
51. TEW WP, Lacchetti C, Kohn EC
    Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Sep 23:JCO2201934. doi: 10.1200/JCO.22.01934.
    PubMed     Abstract available
    
    
    
52. KREMER WW, Dick S, Heideman DAM, Steenbergen RDM, et al
    Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence of FAM19A4/miR124-2 DNA Methylation (CONCERVE Study).
    J Clin Oncol. 2022;40:3037-3046.
    PubMed     Abstract available
    
    
    
53. DISILVESTRO P, Banerjee S, Colombo N, Scambia G, et al
    Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
    J Clin Oncol. 2022 Sep 9:JCO2201549. doi: 10.1200/JCO.22.01549.
    PubMed     Abstract available
    
    
    
54. TANYI JL, Randall LM, Chambers SK, Butler KA, et al
    A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
    J Clin Oncol. 2022 Sep 7:JCO2200291. doi: 10.1200/JCO.22.00291.
    PubMed     Abstract available
    
    
    August 2022
55. SPILSBURY K, Tuesley KM, Pearson SA, Coory MD, et al
    Perioperative Beta-Blocker Supply and Survival in Women With Epithelial Ovarian Cancer and a History of Cardiovascular Conditions.
    J Clin Oncol. 2022 Aug 24:JCO2200097. doi: 10.1200/JCO.22.00097.
    PubMed     Abstract available
    
    
    
56. HAMPEL H, Yurgelun MB
    Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?
    J Clin Oncol. 2022;40:2681-2692.
    PubMed     Abstract available
    
    
    
57. FU S, Corr BR, Culm-Merdek K, Mockbee C, et al
    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
    J Clin Oncol. 2022;40:2568-2577.
    PubMed     Abstract available
    
    
    
58. LI N, Zhang Y, Wang J, Zhu J, et al
    Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
    J Clin Oncol. 2022;40:2436-2446.
    PubMed     Abstract available
    
    
    July 2022
59. HURWITZ LM, Townsend MK, Jordan SJ, Patel AV, et al
    Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.
    J Clin Oncol. 2022 Jul 22:JCO2101900. doi: 10.1200/JCO.21.01900.
    PubMed     Abstract available
    
    
    
60. GEBSKI V, Obermair A, Janda M
    Toward Incorporating Health-Related Quality of Life as Coprimary End Points in Clinical Trials: Time to Achieve Clinical Important Differences and QoL Profiles.
    J Clin Oncol. 2022;40:2378-2388.
    PubMed     Abstract available
    
    
    
61. BETANCOURT NJ, Qian MF, Pickford JR, Bailey-Healy I, et al
    Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity.
    J Clin Oncol. 2022;40:2119-2127.
    PubMed     Abstract available
    
    
    June 2022
62. PHILLIPS KA, Friedlander ML
    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?
    J Clin Oncol. 2022;40:1850-1852.
    PubMed    
    
    
    
63. STEENBEEK MP, van Bommel MHD, Bulten J, Hulsmann JA, et al
    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Clin Oncol. 2022;40:1879-1891.
    PubMed     Abstract available
    
    
    
64. MONK BJ, Parkinson C, Lim MC, O'Malley DM, et al
    A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
    J Clin Oncol. 2022 Jun 6:JCO2201003. doi: 10.1200/JCO.22.01003.
    PubMed     Abstract available
    
    
    May 2022
65. HARPER DM
    Cervical Cancer Elimination Is Dependent on Women's Self-Tests for Primary Human Papillomavirus Testing Triaged by Methylation Status.
    J Clin Oncol. 2022 May 20:JCO2200609. doi: 10.1200/JCO.22.00609.
    PubMed    
    
    
    
66. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
    Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.
    PubMed    
    
    
    
67. LIEBERMAN S, Goldvaser H, Levy-Lahad E
    Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers.
    J Clin Oncol. 2022;40:1590-1594.
    PubMed    
    
    
    
68. LI S, Silvestri V, Leslie G, Rebbeck TR, et al
    Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.
    J Clin Oncol. 2022;40:1529-1541.
    PubMed     Abstract available
    
    
    
69. DONOVAN HS, Sereika SM, Wenzel LB, Edwards RP, et al
    Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259).
    J Clin Oncol. 2022;40:1464-1473.
    PubMed     Abstract available
    
    
    April 2022
70. ASLAN V, Sutcuoglu O, Ozet A, Ozdemir N, et al
    Abscobal Effect of Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer.
    J Clin Oncol. 2022 Apr 29:JCO2200084. doi: 10.1200/JCO.22.00084.
    PubMed    
    
    
    
71. ACHARYA S
    A View on the PARCER Trial.
    J Clin Oncol. 2022;40:1130.
    PubMed    
    
    
    
72. CHOPRA S, Kannan S, Gupta S
    Reply to S. Acharya.
    J Clin Oncol. 2022;40:1130-1131.
    PubMed    
    
    
    March 2022
73. ROQUE DR, Matei D
    Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion.
    J Clin Oncol. 2022;40:924-926.
    PubMed    
    
    
    
74. POWELL MA, Filiaci VL, Hensley ML, Huang HQ, et al
    Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
    J Clin Oncol. 2022;40:968-977.
    PubMed     Abstract available
    
    
    
75. LIU JF, Brady MF, Matulonis UA, Miller A, et al
    Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
    J Clin Oncol. 2022 Mar 15:JCO2102011. doi: 10.1200/JCO.21.02011.
    PubMed     Abstract available
    
    
    
76. DELAHUNTY R, Nguyen L, Craig S, Creighton B, et al
    TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    J Clin Oncol. 2022 Mar 9:JCO2102108. doi: 10.1200/JCO.21.02108.
    PubMed     Abstract available
    
    
    
77. O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
    Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    J Clin Oncol. 2022;40:752-761.
    PubMed     Abstract available
    
    
    February 2022
78. XU Q, Wang J, Sun Y, Lin Y, et al
    Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.
    J Clin Oncol. 2022 Feb 22:JCO2102091. doi: 10.1200/JCO.21.02091.
    PubMed     Abstract available
    
    
    
79. BAEK MH, Park EY, Ha HI, Park SY, et al
    Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis.
    J Clin Oncol. 2022 Feb 21:JCO2102085. doi: 10.1200/JCO.21.02085.
    PubMed     Abstract available
    
    
    
80. ANG BH, Ho WK, Wijaya E, Kwan PY, et al
    Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer.
    J Clin Oncol. 2022 Feb 10:JCO2101647. doi: 10.1200/JCO.21.01647.
    PubMed     Abstract available
    
    
    January 2022
81. LEI J, Arroyo-Muhr LS, Lagheden C, Eklund C, et al
    Human Papillomavirus Infection Determines Prognosis in Cervical Cancer.
    J Clin Oncol. 2022 Jan 25:JCO2101930. doi: 10.1200/JCO.21.01930.
    PubMed     Abstract available
    
    
    
82. BILASH T, Walker LM
    Spare Parts: Navigating Ovarian Cancer as a Transgender Man.
    J Clin Oncol. 2022 Jan 12:JCO2101249. doi: 10.1200/JCO.21.01249.
    PubMed    
    
    
    December 2021
83. O'MALLEY DM, Neffa M, Monk BJ, Melkadze T, et al
    Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
    J Clin Oncol. 2021 Dec 21:JCO2102067. doi: 10.1200/JCO.21.02067.
    PubMed     Abstract available
    
    
    
84. MO DC, Ren T
    Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2021 Dec 10:JCO2102208. doi: 10.1200/JCO.21.02208.
    PubMed    
    
    
    November 2021
85. OONK MHM, Slomovitz B, Baldwin PJW, van Doorn HC, et al
    Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II.
    J Clin Oncol. 2021;39:3623-3632.
    PubMed     Abstract available
    
    
    September 2021
86. PORTER RL, Matulonis UA
    Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer.
    J Clin Oncol. 2021 Sep 16:JCO2101886. doi: 10.1200/JCO.21.01886.
    PubMed    
    
    
    
87. CHOPRA S, Gupta S, Kannan S, Dora T, et al
    Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.
    J Clin Oncol. 2021 Sep 10:JCO2002530. doi: 10.1200/JCO.20.02530.
    PubMed     Abstract available
    
    
    
88. HAMANISHI J, Takeshima N, Katsumata N, Ushijima K, et al
    Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
    J Clin Oncol. 2021 Sep 2:JCO2100334. doi: 10.1200/JCO.21.00334.
    PubMed     Abstract available
    
    
    May 2021
89. ZIVANOVIC O, Chi DS, Zhou Q, Iasonos A, et al
    Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
    J Clin Oncol. 2021 May 21:JCO2100605. doi: 10.1200/JCO.21.00605.
    PubMed     Abstract available
    
    
    
90. MADARIAGA A, Oza AM
    Wee1 Inhibition in Recurrent Serous Uterine Cancer: Science Paving the Way in a Challenging Disease.
    J Clin Oncol. 2021;39:1513-1517.
    PubMed    
    
    
    
91. LIU JF, Xiong N, Campos SM, Wright AA, et al
    Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
    J Clin Oncol. 2021;39:1531-1539.
    PubMed     Abstract available
    
    
    April 2021
92. KONSTANTINOPOULOS PA, Cannistra SA
    Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?
    J Clin Oncol. 2021 Apr 23:JCO2100571. doi: 10.1200/JCO.21.00571.
    PubMed    
    
    
    
93. MOORE KN, Bookman M, Sehouli J, Miller A, et al
    Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
    J Clin Oncol. 2021 Apr 23:JCO2100306. doi: 10.1200/JCO.21.00306.
    PubMed     Abstract available
    
    
    February 2021
94. KURIAN AW, Ward KC, Abrahamse P, Bondarenko I, et al
    Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.